272 related articles for article (PubMed ID: 19622585)
1. HER family receptor abnormalities in lung cancer brain metastases and corresponding primary tumors.
Sun M; Behrens C; Feng L; Ozburn N; Tang X; Yin G; Komaki R; Varella-Garcia M; Hong WK; Aldape KD; Wistuba II
Clin Cancer Res; 2009 Aug; 15(15):4829-37. PubMed ID: 19622585
[TBL] [Abstract][Full Text] [Related]
2. HER family receptor and ligand status in thymic carcinoma.
Weissferdt A; Lin H; Woods D; Tang X; Fujimoto J; Wistuba II; Moran CA
Lung Cancer; 2012 Sep; 77(3):515-21. PubMed ID: 22726920
[TBL] [Abstract][Full Text] [Related]
3. ErbB/HER ligands in human breast cancer, and relationships with their receptors, the bio-pathological features and prognosis.
Révillion F; Lhotellier V; Hornez L; Bonneterre J; Peyrat JP
Ann Oncol; 2008 Jan; 19(1):73-80. PubMed ID: 17962208
[TBL] [Abstract][Full Text] [Related]
4. EGFR and HER3 expression in circulating tumor cells and tumor tissue from non-small cell lung cancer patients.
Scharpenseel H; Hanssen A; Loges S; Mohme M; Bernreuther C; Peine S; Lamszus K; Goy Y; Petersen C; Westphal M; Glatzel M; Riethdorf S; Pantel K; Wikman H
Sci Rep; 2019 May; 9(1):7406. PubMed ID: 31092882
[TBL] [Abstract][Full Text] [Related]
5. Validation of chromogenic in situ hybridization for detection of EGFR copy number amplification in nonsmall cell lung carcinoma.
Sholl LM; John Iafrate A; Chou YP; Wu MT; Goan YG; Su L; Huang YT; Christiani DC; Chirieac LR
Mod Pathol; 2007 Oct; 20(10):1028-35. PubMed ID: 17673923
[TBL] [Abstract][Full Text] [Related]
6. Synchronous overexpression of epidermal growth factor receptor and HER2-neu protein is a predictor of poor outcome in patients with stage I non-small cell lung cancer.
Onn A; Correa AM; Gilcrease M; Isobe T; Massarelli E; Bucana CD; O'Reilly MS; Hong WK; Fidler IJ; Putnam JB; Herbst RS
Clin Cancer Res; 2004 Jan; 10(1 Pt 1):136-43. PubMed ID: 14734462
[TBL] [Abstract][Full Text] [Related]
7. Frequent overexpression of ErbB--receptor family members in brain metastases of non-small cell lung cancer patients.
Berghoff AS; Magerle M; Ilhan-Mutlu A; Dinhof C; Widhalm G; Dieckman K; Marosi C; Wöhrer A; Hackl M; Zöchbauer-Müller S; Preusser M; Birner P
APMIS; 2013 Dec; 121(12):1144-52. PubMed ID: 23756255
[TBL] [Abstract][Full Text] [Related]
8. Neurotensin (NTS) and its receptor (NTSR1) causes EGFR, HER2 and HER3 over-expression and their autocrine/paracrine activation in lung tumors, confirming responsiveness to erlotinib.
Younes M; Wu Z; Dupouy S; Lupo AM; Mourra N; Takahashi T; Fléjou JF; Trédaniel J; Régnard JF; Damotte D; Alifano M; Forgez P
Oncotarget; 2014 Sep; 5(18):8252-69. PubMed ID: 25249545
[TBL] [Abstract][Full Text] [Related]
9. Differential roles of trans-phosphorylated EGFR, HER2, HER3, and RET as heterodimerisation partners of MET in lung cancer with MET amplification.
Tanizaki J; Okamoto I; Sakai K; Nakagawa K
Br J Cancer; 2011 Sep; 105(6):807-13. PubMed ID: 21847121
[TBL] [Abstract][Full Text] [Related]
10. [Comparison of EGFR and KRAS status between primary non-small cell lung cancer and corresponding metastases: a systematic review and meta-analysis].
Han C; Zou H; Ma J; Zhou Y; Zhao J
Zhongguo Fei Ai Za Zhi; 2010 Sep; 13(9):882-91. PubMed ID: 20840818
[TBL] [Abstract][Full Text] [Related]
11. Association between epidermal growth factor receptor gene copy number and ERCC1, BRCA1 protein expression in Chinese patients with non-small cell lung cancer.
Zhang Y; Yang H; Qiu Y; Deng Q; Liu J; Zhao M; He P; Mo M; Zou X; He J
Med Oncol; 2014 Mar; 31(3):803. PubMed ID: 24452282
[TBL] [Abstract][Full Text] [Related]
12. HER4 and EGFR Activate Cell Signaling in NRG1 Fusion-Driven Cancers: Implications for HER2-HER3-specific Versus Pan-HER Targeting Strategies.
Udagawa H; Nilsson MB; Robichaux JP; He J; Poteete A; Jiang H; Heeke S; Elamin YY; Shibata Y; Matsumoto S; Yoh K; Okazaki S; Masuko T; Odintsov I; Somwar R; Ladanyi M; Goto K; Heymach JV
J Thorac Oncol; 2024 Jan; 19(1):106-118. PubMed ID: 37678511
[TBL] [Abstract][Full Text] [Related]
13. Ligand-Independent Epidermal Growth Factor Receptor Overexpression Correlates with Poor Prognosis in Colorectal Cancer.
Yun S; Kwak Y; Nam SK; Seo AN; Oh HK; Kim DW; Kang SB; Lee HS
Cancer Res Treat; 2018 Oct; 50(4):1351-1361. PubMed ID: 29361822
[TBL] [Abstract][Full Text] [Related]
14. EGF receptor activates MET through MAPK to enhance non-small cell lung carcinoma invasion and brain metastasis.
Breindel JL; Haskins JW; Cowell EP; Zhao M; Nguyen DX; Stern DF
Cancer Res; 2013 Aug; 73(16):5053-65. PubMed ID: 23794705
[TBL] [Abstract][Full Text] [Related]
15. Comparison between epidermal growth factor receptor (EGFR) gene expression in primary non-small cell lung cancer (NSCLC) and in fine-needle aspirates from distant metastatic sites.
Bozzetti C; Tiseo M; Lagrasta C; Nizzoli R; Guazzi A; Leonardi F; Gasparro D; Spiritelli E; Rusca M; Carbognani P; Majori M; Franciosi V; Rindi G; Ardizzoni A
J Thorac Oncol; 2008 Jan; 3(1):18-22. PubMed ID: 18166836
[TBL] [Abstract][Full Text] [Related]
16. The G Protein-Coupled Receptor PAC1 Regulates Transactivation of the Receptor Tyrosine Kinase HER3.
Moody TW; Lee L; Jensen RT
J Mol Neurosci; 2021 Aug; 71(8):1589-1597. PubMed ID: 32964398
[TBL] [Abstract][Full Text] [Related]
17. Epidermal growth factor receptor abnormalities in the pathogenesis and progression of lung adenocarcinomas.
Tang X; Varella-Garcia M; Xavier AC; Massarelli E; Ozburn N; Moran C; Wistuba II
Cancer Prev Res (Phila); 2008 Aug; 1(3):192-200. PubMed ID: 19138956
[TBL] [Abstract][Full Text] [Related]
18. Clinicopathologic features and prognostic implications of epidermal growth factor receptor (EGFR) gene copy number and protein expression in non-small cell lung cancer.
Jeon YK; Sung SW; Chung JH; Park WS; Seo JW; Kim CW; Chung DH
Lung Cancer; 2006 Dec; 54(3):387-98. PubMed ID: 17011067
[TBL] [Abstract][Full Text] [Related]
19. Expression of the ERBB Family of Ligands and Receptors in Gastric Cancer.
Byeon SJ; Lee HS; Kim MA; Lee BL; Kim WH
Pathobiology; 2017; 84(4):210-217. PubMed ID: 28399526
[TBL] [Abstract][Full Text] [Related]
20. Overcoming acquired resistance to cetuximab by dual targeting HER family receptors with antibody-based therapy.
Iida M; Brand TM; Starr MM; Huppert EJ; Luthar N; Bahrar H; Coan JP; Pearson HE; Salgia R; Wheeler DL
Mol Cancer; 2014 Oct; 13():242. PubMed ID: 25344208
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
